We use essential cookies to operate our site. With your consent, we may also use non-essential cookies to improve your user experience and to analyze website traffic. Click "Accept" to accept cookies and go directly to the site, click "Reject" to reject all but cookies strictly necessary for the functioning of this site. You can reset your cookie settings at any time by visiting your Bioz "my account" page and selecting the "reset cookie preferences" link.

Accept Reject

Overview
Images
Article Snippets
home > search results > product details
star_border
     Loading Product Details ...      Welcome to Your Next Discovery   
96 / 100
Bioz Stars

Santa Cruz  
Product Name
Saccharomyces cerevisiae Meyen ex E C Hansen
Catalog Number
4024814
Biosafety Level
1
Genotype
MATa/MATalpha his3delta1/his3delta1 leu2delta0/leu2delta0 lys2delta0/+ met15delta0/+ ura3delta0/ura3delta0 deltaUBR1
Category
Fungi
Product Format
Frozen
More Catalog Fields ...
Open an account
already a user? Sign in
are you a supplier? Contact us
Product Images (1) - All
All
Binding Assay
Luciferase
Mutagenesis
Transfection
Western Blot
MUC4-promoted neural invasion is mediated by the axon guidance factor netrin-1 in PDAC 
star_border
A. Western blot analysis for <t>pHER2,</t> HER2, pAKT, AKT, pIκBα, IκBα, pNF-κB, NF-κB and netrin-1 in Scr-treated and shMUC4-treated cells, GAPDH was used as a control. B. Western blot analysis for pHER2, HER2 and netrin-1 in Scr-treated and shHER2-treated cells, GAPDH was used as a control. C. Colo-357and Capan-1 cells were treatment with AKT inhibitor for 0h, 3h, 6h and 9h. AKT, pAKT and netrin-1 protein levels were determined by western blot analysis. GAPDH was used as a control. D. Colo-357 and Capan-1 cells were treatment with NF-κB inhibitor for 0h, 3h, 6h and 9h. NF-κB, pNF-κB and netrin-1 protein levels were determinedby western blot analysis. GAPDH was used as a control. E. Schematic representation of the 5′-flanking NTN1 genomic region. Clonedpromoter (shaded box), first exons (black box), NF-κB (p65) binding site, which was identified using the TFSEARCH program, corresponding to nucleotides −307 to −298 (relative to the putative transcription start site +1) F. Scr-treated Colo-357 and shMUC4-treated Colo-357 cells were transfected with pGL3-NTN1 WT or pGL3-NTN1 mutant (preventing NF-κB binding) for 24 h and lysed for the luciferase activity assay. Promoter activity was normalized to pGL3-NTN1WT-transfected Colo-357 Scr cells. The data are presented as mean ± SEM. * p < 0.05. G. Scr-treated Capan-1 and shMUC4-treated Capan-1 cells were transfected with pGL3-NTN1 WT or pGL3-NTN1 mutant (preventing NF-κB binding) for 24 hand lysed for the luciferase activity assay. Promoter activity was normalized to pGL3-NTN1 WT-transfected Capan-1 Scr cells. The data are presented as mean ± SEM. * p < 0.05. H. Western blot analysis for pFAK, FAK, pSrc, Src, pJNK, JNK and MMP9 in Scr-treated and shMUC4-treated cells, GAPDH was used as a control.
MUC4-promoted neural invasion is mediated by the axon guidance factor netrin-1 in PDAC Oncotarget, 2015 Oct 20
"A. Western blot analysis for <t>pHER2,</t> HER2, pAKT, AKT, pIκBα, IκBα, pNF-κB, NF-κB and netrin-1 in Scr-treated and shMUC4-treated cells, GAPDH was used as a control. B. Western blot analysis for pHER2, HER2 and netrin-1 in Scr-treated and shHER2-treated cells, GAPDH was used as a control. C. Colo-357and Capan-1 cells were treatment with AKT inhibitor for 0h, 3h, 6h and 9h. AKT, pAKT and netrin-1 protein levels were determined by western blot analysis. GAPDH was used as a control. D. Colo-357 and Capan-1 cells were treatment with NF-κB inhibitor for 0h, 3h, 6h and 9h. NF-κB, pNF-κB and netrin-1 protein levels were determinedby western blot analysis. GAPDH was used as a control. E. Schematic representation of the 5′-flanking NTN1 genomic region. Clonedpromoter (shaded box), first exons (black box), NF-κB (p65) binding site, which was identified using the TFSEARCH program, corresponding to nucleotides −307 to −298 (relative to the putative transcription start site +1) F. Scr-treated Colo-357 and shMUC4-treated Colo-357 cells were transfected with pGL3-NTN1 WT or pGL3-NTN1 mutant (preventing NF-κB binding) for 24 h and lysed for the luciferase activity assay. Promoter activity was normalized to pGL3-NTN1WT-transfected Colo-357 Scr cells. The data are presented as mean ± SEM. * p < 0.05. G. Scr-treated Capan-1 and shMUC4-treated Capan-1 cells were transfected with pGL3-NTN1 WT or pGL3-NTN1 mutant (preventing NF-κB binding) for 24 hand lysed for the luciferase activity assay. Promoter activity was normalized to pGL3-NTN1 WT-transfected Capan-1 Scr cells. The data are presented as mean ± SEM. * p < 0.05. H. Western blot analysis for pFAK, FAK, pSrc, Src, pJNK, JNK and MMP9 in Scr-treated and shMUC4-treated cells, GAPDH was used as a control. "
Protocol Conditions
Article Snippets for All Techniques